Skip to content
value.today
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc.

Total raised
$195 M
2 rounds on record
Latest round
$173 M
Mar 2021
First round on record
Jun 2019
Today
Went public
See the company page

Pyxis Oncology, Inc. is listed today as Pyxis Oncology, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pyxis Oncology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2021$173 MNo. 2$50 to $250 million

Pyxis Oncology, Inc.: Raise no. 2, Mar 2021

Investors in this round

38 investors had bought by the notice of Mar 22, 2021: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Pyxis Oncology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$173 M of $173 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lara Sullivan · Executive Officer, Director
  • Robert Crane · Executive Officer
  • Christian Schetter · Director
  • Christopher O?Donnell · Director
  • David Steinberg · Director
  • Gotham Makker · Director
  • John Flavin · Director
  • Lucio Iannone · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lara Sullivan, Chief Executive Officer. Newest notice filed Mar 22, 2021. Read the notice at the SEC.

equitySEC
Jun 2019$22 MNo. 1$10 to $50 million

Pyxis Oncology, Inc.: Raise no. 1, Jun 2019

Investors in this round

9 investors had bought by the notice of Jul 12, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Pyxis Oncology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Steinberg · Executive Officer, Director
  • Christoph Westphal · Director
  • Geeta Vemuri · Director
  • Jak Knowles · Director
  • John Flavin · Director
  • Lucio Iannone · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Steinberg, Chief Executive Officer. Newest notice filed Jul 12, 2019. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Pyxis Oncology, Inc., its revenue in fiscal 2025 came from these product and service lines: Sale of Royalty Rights $11.04 million (80%), Milestone Revenue $2.82 million (20%).

    Annual report (SEC XBRL) · Dec 2025

  • Pyxis Oncology, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2021).

    SEC Form D · Mar 2021

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Mar 2021

Products and services#

No products or services of Pyxis Oncology, Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Pyxis Oncology, Inc.
InvestorKindAmountRoundRoleSource
Bayer World Investments B.V.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund III LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
John L. FlavinPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2021)SEC Form 3

Largest shareholders today

Institutions holding Pyxis Oncology, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pyxis Oncology, Inc.
NameRoleNamed in
Lara SullivanExecutive officerMar 2021
Robert CraneExecutive officerMar 2021
David SteinbergExecutive officerJul 2019
Christian SchetterDirectorMar 2021
Christopher O?DonnellDirectorMar 2021
David SteinbergDirectorMar 2021
Gotham MakkerDirectorMar 2021
John FlavinDirectorMar 2021
Lara SullivanDirectorMar 2021
Lucio IannoneDirectorMar 2021
Christoph WestphalDirectorJul 2019
Geeta VemuriDirectorJul 2019
Jak KnowlesDirectorJul 2019

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.